These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson's Disease. Karunaratne TB; Okereke C; Seamon M; Purohit S; Wakade C; Sharma A Nutrients; 2020 Dec; 13(1):. PubMed ID: 33374784 [TBL] [Abstract][Full Text] [Related]
11. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential. Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183 [TBL] [Abstract][Full Text] [Related]
12. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Singh N; Gurav A; Sivaprakasam S; Brady E; Padia R; Shi H; Thangaraju M; Prasad PD; Manicassamy S; Munn DH; Lee JR; Offermanns S; Ganapathy V Immunity; 2014 Jan; 40(1):128-39. PubMed ID: 24412617 [TBL] [Abstract][Full Text] [Related]
13. The Role of GPR109a Signaling in Niacin Induced Effects on Fed and Fasted Hepatic Metabolism. Geisler CE; Miller KE; Ghimire S; Renquist BJ Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924461 [TBL] [Abstract][Full Text] [Related]
14. Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via Gβγ/PKC/ERK1/2 pathway and heterologous receptor desensitization. Shi Y; Lai X; Ye L; Chen K; Cao Z; Gong W; Jin L; Wang C; Liu M; Liao Y; Wang JM; Zhou N Sci Rep; 2017 Feb; 7():42279. PubMed ID: 28186140 [TBL] [Abstract][Full Text] [Related]
15. Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets. Chen L; So WY; Li SY; Cheng Q; Boucher BJ; Leung PS Mol Cell Endocrinol; 2015 Mar; 404():56-66. PubMed ID: 25622782 [TBL] [Abstract][Full Text] [Related]
16. Niacin Ameliorates Neuro-Inflammation in Parkinson's Disease via GPR109A. Giri B; Belanger K; Seamon M; Bradley E; Purohit S; Chong R; Morgan JC; Baban B; Wakade C Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540057 [TBL] [Abstract][Full Text] [Related]
17. Niacin fine-tunes energy homeostasis through canonical GPR109A signaling. Ye L; Cao Z; Lai X; Wang W; Guo Z; Yan L; Wang Y; Shi Y; Zhou N FASEB J; 2019 Apr; 33(4):4765-4779. PubMed ID: 30596513 [TBL] [Abstract][Full Text] [Related]
18. Niacin receptor GPR109A inhibits insulin secretion and is down-regulated in type 2 diabetic islet beta-cells. Wang N; Guo DY; Tian X; Lin HP; Li YP; Chen SJ; Fu YC; Xu WC; Wei CJ Gen Comp Endocrinol; 2016 Oct; 237():98-108. PubMed ID: 27570060 [TBL] [Abstract][Full Text] [Related]
19. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621 [TBL] [Abstract][Full Text] [Related]
20. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. Pike NB J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]